A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC)
- PMID: 23443227
- PMCID: PMC6442753
- DOI: 10.4104/pcrj.2013.00016
A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC)
Abstract
After the development of the COPD Strategy of the National Health Service in Spain, all scientific societies, patient organisations, and central and regional governments formed a partnership to enhance care and research in COPD. At the same time, the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) took the initiative to convene the various scientific societies involved in the National COPD Strategy and invited them to participate in the development of the new Spanish guidelines for COPD (Guía Española de la EPOC; GesEPOC). Probably the more innovative approach of GesEPOC is to base treatment of stable COPD on clinical phenotypes, a term which has become increasingly used in recent years to refer to the different clinical forms of COPD with different prognostic implications. The proposed phenotypes are: (A) infrequent exacerbators with either chronic bronchitis or emphysema; (B) overlap COPD-asthma; (C) frequent exacerbators with emphysema predominant; and (D) frequent exacerbators with chronic bronchitis predominant. The assessment of severity has also been updated with the incorporation of multidimensional indices. The severity of the obstruction, as measured by forced expiratory volume in 1 second, is essential but not sufficient. Multidimensional indices such as the BODE index have shown excellent prognostic value. If the 6-minute walking test is not performed routinely, its substitution by the frequency of exacerbations (BODEx index) provides similar prognostic properties. This proposal aims to achieve a more personalised management of COPD according to the clinical characteristics and multidimensional assessment of severity.
Conflict of interest statement
MM has received honoraria for lecturing or scientific advice from Boehringer Ingelheim (BI), Pfizer, AstraZeneca (AZ), Bayer Healthcare, Novartis, Talecris, Takeda-Nycomed, Merck, Sharp & Dohme (MSD), Novartis, GlaxoSmithKline (GSK) and Almirall. PA has received honoraria for lecturing, research funds or scientific advice from BI, Pfizer, Takeda-Nycomed, MSD, Almirall, GSK, Chiesi and Esteve. JA has received honoraria for lecturing, research funds or scientific advice from BI, Novartis, Takeda-Nycomed, Almirall, GSK, Intermunne, Faes Farma, Chiesi and Actelion. MC has received honoraria for lecturing, research funds or scientific advice from Carburos Médica, AZ, MSD and Almirall. JJS-C has received honoraria for lecturing, research funds or scientific advice from BI, Pfizer, AZ, Bayer Schering, Novartis, Takeda-Nycomed, MSD, Almirall, Grupo Ferrer, GSK and Vifor Pharma. JBS has received honoraria for lecturing, research funds or scientific advice from Almirall. JAT has received honoraria for lecturing, research funds or scientific advice from BI, Pfizer and Bayer Healthcare. JM, PP, JAQ, JAR and AS have no conflict of interest in relation to this article.
Figures
References
-
- National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. 2010. London: National Clinical Guideline Centre. Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/English
-
- Nagai A, Aizawa H, Aoshiba K, et al. Guidelines for the diagnosis and treatment of COPD. 3rd ed. Tokyo: The Japanese Respiratory Society Medical Review Co Ltd, 2009.
-
- Estrategia del Sistema Nacional de Salud en EPOC. Ministerio de Salud y Política Social, Madrid, 2009.
-
- Boletin Oficial del Estado. Ley 42/2010, de 30 de diciembre, por la que se modifica la Ley 28/2005, de 26 de diciembre, de medidas sanitarias frente al tabaquismo y reguladora de la venta, el suministro, el consumo y la publicidad de los productos del tabaco.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical